A drug commonly used to treat Type 2 diabetes in adults has been found to have links to possible bone fragility and bone loss.

The drug, according to a study published in Nature Magazine, has been identified as Avandia, more commonly known as rosiglitazone

The U.S. Food and Drug Administration (FDA) said on Tuesday that GlaxoSmithKline Plc. and Takeda Pharmaceutical Company Ltd. have agreed to include "black- box" warnings for the controversial diabetes drugs Avandia and Actos.

The warnings, the strictest ever a prescription drugs can bear, means that the medicines can cause or worsen heart failure. The patients are advised to closely monitor the medicine for symptoms

Panelists from the U.S. Food and Drug Administration (FDA) on Monday approved the widely used diabetes drug Avandia to remain on the market by a 22-1 vote. FDA advisers ruled that current evidence linking the Type-2 diabetes drug to an increased risk of heart attack is not strong enough to order Avandia's removal from the market.

The panel also recommended that Avandia, also known as rosiglitazone, should be studied further and should carry a "black-box" warning. Some experts also suggested the label caution against using the drug together with insulin, because current studies suggest that doing so may elevate heart risks. Nonetheless, the joint use of Avandia and insulin is currently FDA-approved

The U.S. Food and Drug Administration has reportedly issued a warning concerning the drug Avandia (rosiglitazone) - a drug used to treat type 2 diabetes.

The FDA says safety data from controlled clinical trials has shown a potentially significant increase in the risk of heart attack and heart-related deaths in patients taking Avandia. The study shows that Avandia increases heart attack risk by 43 percent and increases risk of death from heart disease by 64 percent

A provocative new theory suggests one root cause of Alzheimer's disease may be halted by a diabetes drug. The new theory will be tested in thousands of Alzheimer's patients taking Avandia.

A preliminary experiment involving 511 Alzheimer's patients found signs that Avandia might help quell the disease in people who lack a gene that spurs more aggressive Alzheimer's